These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia. Michiels JJ, Berneman Z, Schroyens W, Koudstaal PJ, Lindemans J, Neumann HA, van Vliet HH. Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481 [Abstract] [Full Text] [Related]
3. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Michiels JJ, Berneman Z, Schroyens W, Finazzi G, Budde U, van Vliet HH. Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569 [Abstract] [Full Text] [Related]
4. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W. Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274 [Abstract] [Full Text] [Related]
5. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis. Bucalossi A, Marotta G, Bigazzi C, Galieni P, Dispensa E. Am J Hematol; 1996 May; 52(1):14-20. PubMed ID: 8638606 [Abstract] [Full Text] [Related]
9. Pathogenesis and management of bleeding in essential thrombocythemia and polycythemia vera. Elliott MA, Tefferi A. Curr Hematol Rep; 2004 Sep; 3(5):344-51. PubMed ID: 15341701 [Abstract] [Full Text] [Related]
10. Leukocytosis at diagnosis and the risk of subsequent thrombosis in patients with low-risk essential thrombocythemia and polycythemia vera. Gangat N, Wolanskyj AP, Schwager SM, Hanson CA, Tefferi A. Cancer; 2009 Dec 15; 115(24):5740-5. PubMed ID: 19806641 [Abstract] [Full Text] [Related]
12. Arterial stenosis and atherothrombotic events in polycythemia vera and essential thrombocythemia. Cucuianu A, Stoia M, Farcaş A, Dima D, Zdrenghea M, Paţiu M, Olinic D, Petrov L. Rom J Intern Med; 2006 Dec 15; 44(4):397-406. PubMed ID: 18386616 [Abstract] [Full Text] [Related]
15. Evaluation of interleukin-23 plasma levels in patients with polycythemia vera and essential thrombocythemia. Gangemi S, Allegra A, Pace E, Alonci A, Ferraro M, Petrungaro A, Saitta S, Gerace D, Russo S, Penna G, Musolino C. Cell Immunol; 2012 Dec 15; 278(1-2):91-4. PubMed ID: 23121980 [Abstract] [Full Text] [Related]
16. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Falanga A, Marchetti M, Evangelista V, Vignoli A, Licini M, Balicco M, Manarini S, Finazzi G, Cerletti C, Barbui T. Blood; 2000 Dec 15; 96(13):4261-6. PubMed ID: 11110700 [Abstract] [Full Text] [Related]
17. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Murphy S. Semin Hematol; 1999 Jan 15; 36(1 Suppl 2):9-13. PubMed ID: 9930551 [Abstract] [Full Text] [Related]